Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease